Presentation Highlights Clinical Potential of Navidea Biopharmaceuticals’ ß-Amyloid Imaging Biomarker AZD4694

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced Phase 1 and Phase 2 clinical trials data from its radiopharmaceutical candidate, AZD4694 for the detection of amyloid in patients with Alzheimer's disease, were presented at the recent 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy meeting. The bi-annual conference focuses on pharmacological therapy in Alzheimer’s disease (AD) and is organized by the Karolinska Institute, Sweden, University of Geneva, Switzerland, and Southern Illinois University, U.S. The three-day meeting featured world leaders in Alzheimer’s disease innovation discussing new trial designs, animal models, and neuroimaging including PET and diagnostic recommendations. In December 2011 Navidea announced that it had in-licensed the worldwide rights for AZD4694 from AstraZeneca.